Why Juno Therapeutics Is Our Favorite Immuno-Oncology Pick For 2017?

JUNO

Juno Therapeutics (JUNO) presented Q1, 2017 earnings and pipeline update last week. The company is recovering well from the setback of the ROCKET trial and seems well positioned to have at least one commercial CAR-T product in the market in 2018.

(Juno Therapeutics: common stock price chart)

Non-Ho...

Juno Therapeutics (JUNO) presented Q1, 2017 earnings and pipeline update last week. The company is recovering well from the setback of the ROCKET trial and seems well positioned to have at least one commercial CAR-T product in the market in 2018.

(Juno Therapeutics: common stock price chart)

Non-Ho...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics